Archives

by in
Entry Author Date Location
Icahn Jabs Biogen Idec, Says Its Board Had `Very Little’ Input in Sale Process 06/05/08 Boston
Indevus Drug Delayed by FDA Safety Questions, Shares Plummet 06/04/08 Boston
Evergreen Rakes in the Green, NxStage Plans Two-Stage Deal, Atlas Places Big Bet on MicroRNA, & More Deals News 05/27/08 Boston
Shares of Evergreen Solar Shine After $1 Billion Contract News 05/22/08 Boston
Geezeo Takes a Walk on The Sunny Side of TheStreet.com 04/24/08 Boston
Dynogen, Apex Call Off Reverse Merger 04/17/08 Boston
Monotype Files for SPO 04/02/08 Boston
RXi’s Debut, Sirtris’ Surprising Deal, Hydra’s Big Financing Round, & More of the Last Week in Life Sciences 03/19/08 Boston
Diomed Files for Bankruptcy, Plans Sale 03/14/08 Boston
Mello RNAi Firm RXi Pharmaceuticals Has Wild Ride on First Day of Trading 03/12/08 Boston
Curis, Alkermes Down on News of Failed Pharma Partnerships 03/10/08 Boston
AspenTech Delisted from NASDAQ 02/15/08 Boston
With a Whole Lot of Spending to Do, Vertex Seeks Some $400 Million in Stock and Note Offerings 02/13/08 Boston
Evergreen Solar Plans Offering, ThingMagic Teams With Ford, Dynogen Reverse-Merges Onto the Market, & More 02/12/08 Boston
Targanta Files for FDA Approval of Anti-MRSA Drug 02/11/08 Boston
Dynogen Goes Public Via Reverse Merger 02/06/08 Boston
Evergreen Solar Plans $230M Secondary Offering 02/04/08 Boston
Elixir Postpones IPO 01/17/08 Boston
Elixir, NameMedia, Archemix, and More: What’s on Tap for New England IPOs in 2008 01/11/08 Boston
Vertex Falls On Hepatitis Drug Delay Reports 01/04/08 Boston
Glasshouse Plots for VMware IPO Sequel, Idera Partners With Merck, iRobot Inks Deal With Army, & More 12/24/07 Boston
Elixir Sets Price Target for IPO 12/19/07 Boston
Nuance Cuts Stock Offering Size 12/19/07 Boston
Harvard Bioscience to Buy Back $10M in Stock 12/07/07 Boston
Inverness Nets $806.4M in Stock Sale 11/21/07 Boston
Inverness Prices Secondary Public Offering, Nearly Doubling Its Size 11/15/07 Boston
Verenium Files $150 Million Shelf Registration 11/15/07 Boston
Insulet Prices SPO 11/07/07 Boston
Genzyme CEO Nets $9.3 Million From Options 10/31/07 Boston
EnerNOC Plans Secondary Offering 10/29/07 Boston
Page 2 of 3 « previous page · next page »